BioPharma Terug naar discussie overzicht

Ook SIRNA

1. [verwijderd] 5 april 2006 11:02

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   ludwig mack schreef:

   de waarde is niet reel nu, met een cramer die blijkbaar al weken zijn klanten het aandeel aanbeveelt; bij desinteresse kan het fel terugzakken, en dus link.
   

   Ben het met je eens, de waarde van het aandeel hoort veel hoger te zijn. 1200 miljoen clinical milestones in de komende jaren en nog veel meer deals dit jaar en volgend jaar. Huidige waarde nog maar 500 miljoen bij deze koers.
   
   CEO gaat vanmiddag de nasdaq openen. Hopelijk goed voor meer nieuws berichten.
2. [verwijderd] 8 april 2006 08:49

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Nog een klein stukje over Sirna:
   
   Under the Radar
   
   Fiscal Therapy
   
   By Lawrence Carrel Published: April 7, 2006
   Click here for more stories by Lawrence Carrel.
   StockCompare
   
   
   Here's our weekly look at some small-capitalization stocks that are making big moves on Wall Street.
   
   EVEN AS NAYSAYERS PREDICT the end of the rally in small-cap stocks, the major indexes continue to set records. The Russell 2000 closed at an all-time high of 766.26 on Wednesday. The S&P SmallCap 600's close peaked at 396.21, also on Wednesday.
   
   Emboldening small-cap bulls are the performances of stocks like Sirna Therapeutics (RNAI: 7.81, -0.08, -1.0%). The biotech's shares rallied 17% to $7.89 this week (through Thursday) thanks to a deal with GlaxoSmithKline (GSK: 51.48, -0.39, -0.8%). The world's second-largest pharmaceutical company agreed on Monday to an exclusive multiyear strategic alliance with Sirna, based in Boulder, Colo. The agreement centers around the development and commercialization of gene-based treatments for respiratory diseases.
   
   The terms look favorable for Sirna, which posted a net loss of $23.9 million on revenues of just $4.9 million last year. The company will receive an initial $12 million payment from Glaxo which should help offset the $25 million in cash management expects to burn through in 2006. Assuming successful development of novel RNA interference-based therapies, Sirna could ultimately pocket more than $700 million from milestone payments and royalties on world-wide sales.
   
   RNA interference is a natural process for turning off genes. Sirna has created a platform technology that makes synthetic short interfering RNA (siRNA), which can halt the replication of viruses or prevent the expression and creation of proteins that lead to disease. The company anticipates that this technology can be used against many diseases. Under the agreement, Sirna will provide formulated short interfering RNA compounds for Glaxo's targets. At that point the British drug giant will assume responsibility for all further preclinical and clinical development, as well as commercialization of the products.
   
   "I think this is the first of several deals," says Jonathan Aschoff, an analyst at New York investment bank Brean Murray Carret & Co. "The Glaxo deal only covers pulmonary diseases. Oncology and everything else, except macular degeneration, are fully open. They can slice them up how they want. There's the potential for more deals that could reach $3.5 billion in milestone payments. I don't think this stock is fully valued yet." (Brean Murray Carret has an investment-banking relationship with Sirna.)
   
   Sirna has no drugs on the market and has never posted a profit. But it does have a deep pipeline. In addition to the respiratory program with Glaxo, it has an alliance with Allergan (AGN: 104.09, -1.46, -1.4%) on a compound for the wet form of age-related macular degeneration. This is expected to enter Phase II clinical trials later this year. Sirna's therapy for hepatitis C is expected to enter a Phase I trial by early 2007. It also has preclinical programs dealing with dermatology, oncology and Huntington's disease.
   
   Also on Monday, the Patent and Trademark Office awarded Sirna its first target patent in the U.S. It covers any chemically modified short interfering RNA targeting I Kappa B kinase-gamma (IKK-gamma), an important mediator in a host of conditions including asthma, arthritis, cancer, chronic inflammation, neurodegenerative diseases and heart disease.
   
   "The big deal here is that it's not limited to a specific sequence," says Rebecca Galler Robison, Sirna's senior director of corporate strategy. "The U.S. patent covers any siRNA sequence against the targeted gene." Sirna has patents pending for more than 250 mammalian disease targets including Parkinson's, Alzheimer's and HIV.
   
   Unlike many biotechs, Sirna has the good fortune of not having its future tied up in just one or two drugs. But like most biotechs it's an extremely speculative investment. Even under the best of conditions drugs take many years to gain regulatory approval. Most never do. That's why we always recommend that investors commit only a small portion of an overall portfolio to individual small-cap stocks.
   
   
3. ludwig mack 10 april 2006 20:35

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   daar gaat de koers al ........
4. [verwijderd] 12 april 2006 14:39

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   biz.yahoo.com/bw/060412/2006041200535...
   
   Alnylam To Collaborate with United States Army on RNAi Therapeutics for Biodefense Threats
   Wednesday April 12, 8:00 am ET
   
   CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 12, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, Alnylam will collaborate with USAMRIID to discover RNAi therapeutics targeting viral organisms, including hemorrhagic fever viruses, which pose a serious biological threat to the military and public health of the United States.
   (...)
   
   ...Dit zou wel eens voor vuurwerk (of veenbrand als'k het nu goed inschat) kunnen zorgen!
   
   Geluk, F.
5. [verwijderd] 12 april 2006 15:36

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Vooralsnog een lose canon ipv vuurwerk: --3%
   
   P.
6. [verwijderd] 12 april 2006 21:45

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   psycho-pharma schreef:

   Vooralsnog een lose canon ipv vuurwerk: --3%
   
   P.
   

   nu + 2,5%
   Entremed lift mee: +6%
   
   P.
7. [verwijderd] 19 april 2006 21:51

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Het blijft een raar koersverloop, vorig week nog onder de 7 en kijk nu.
   
   Er zijn nu trouwens ook opties.
8. [verwijderd] 19 april 2006 22:04

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Op zich geen vreemd koersverloop, na een flinke stijging gaan we altijd een stap(je) terug om vervolgens weer 2 stappen voorwaarts te zetten, en met een voorlopig hoogste slotstand van dit jaar van $ 8,19 lijkt dit aardig te gaan lukken.
9. [verwijderd] 21 april 2006 09:15

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Heerlijk, toch weer een slotstand die wat hoger was dan daags te voren, gesloten op $ 8,36.
10. [verwijderd] 1 mei 2006 17:27

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    UPDATE 1-Inex files counterclaim against Protiva
    Mon May 1, 2006 9:30 AM ET
    
    (Adds details)
    
    TORONTO, May 1 (Reuters) - Inex Pharmaceuticals Corp. <IEX.TO> said on Monday it has filed a counterclaim against Protiva Biotherapeutics Inc. regarding drug delivery rights for a class of drugs known as oligonucleotides.
    
    The dispute with Protiva, which was spun out from Inex in 2001, was filed in the Superior Court of British Columbia and states that any technological advancements by Protiva for the delivery of oligonucleotides, are either owned by Inex or should be licensed to Inex.
    
    Last week, Protiva filed separate lawsuits against Inex and Sirna Therapeutics Inc. <RNAI.O> over its delivery technologies for a type of drug known as small interfering RNA therapeutics.
    
    Protiva said Sirna ended its strategic alliance with the company last month by filing suit against Protiva in violation of the parties' dispute resolution agreements.
    
    Protiva said it believes that Sirna's filing was instigated in part by false claims Inex has made about Protiva's rights.
    
    koers 7.9
12. [verwijderd] 1 mei 2006 17:57

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Jommeke schreef:

    UPDATE 1-Inex files counterclaim against Protiva
    Mon May 1, 2006 9:30 AM ET
    
    (Adds details)
    
    TORONTO, May 1 (Reuters) - Inex Pharmaceuticals Corp. <IEX.TO> said on Monday it has filed a counterclaim against Protiva Biotherapeutics Inc. regarding drug delivery rights for a class of drugs known as oligonucleotides.
    
    The dispute with Protiva, which was spun out from Inex in 2001, was filed in the Superior Court of British Columbia and states that any technological advancements by Protiva for the delivery of oligonucleotides, are either owned by Inex or should be licensed to Inex.
    
    Last week, Protiva filed separate lawsuits against Inex and Sirna Therapeutics Inc. <RNAI.O> over its delivery technologies for a type of drug known as small interfering RNA therapeutics.
    
    Protiva said Sirna ended its strategic alliance with the company last month by filing suit against Protiva in violation of the parties' dispute resolution agreements.
    
    Protiva said it believes that Sirna's filing was instigated in part by false claims Inex has made about Protiva's rights.
    
    koers 7.9
    

    Is niet de reden van de stijging, maar wel dit geweldige bericht van ALNY over RNAI-techniek:
    Press Release Source: Alnylam Pharmaceuticals, Inc.
    
    Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection
    Sunday April 30, 7:15 pm ET
    Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 30, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that the company's lead product candidate, ALN-RSV01, was found to be safe and well tolerated when administered intranasally in two Phase I clinical studies. ALN-RSV01 is being evaluated for the treatment of respiratory syncytial virus (RSV) infection and is the first RNAi therapeutic in human clinical development for an infectious disease.
    ADVERTISEMENT
    
    
    "These Phase I study results are an important step forward for Alnylam and for the entire field of RNAi therapeutics. Data from these trials provide us with a significant clinical experience for ALN-RSV01 with 101 subjects enrolled in the two trials combined," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "Treatment of RSV infection, the leading cause of pediatric hospitalization in the U.S. today and a prevalent infection in certain adult populations, represents a major unmet medical need in a large number of patients. We believe that ALN-RSV01 is a promising treatment option for these patients and, as an unpartnered clinical program, an important component of Alnylam's balanced pipeline of wholly owned and partnered RNAi therapeutics."
    
    "As a clinician committed to the advancement of new therapies for the treatment of pediatric infectious diseases, I am very encouraged by the results of these first human studies with ALN-RSV01," said John P. DeVincenzo, M.D., Associate Professor of Pediatrics at the University of Tennessee Health Science Center. "Based on these Phase I studies, the encouraging pre-clinical data showing anti-viral activity at similar doses, and the drug's novel mechanism of action, ALN-RSV01 may represent a breakthrough treatment option for patients infected with RSV."
    
    Alnylam conducted two Phase I trials with ALN-RSV01 to evaluate the safety, tolerability, and pharmacokinetics of ALN-RSV01 in healthy adult volunteers. Both trials were double-blind, placebo-controlled, and randomized. In total, 101 subjects were enrolled in the trials and 65 were exposed to ALN-RSV01. The subjects received single or multiple daily doses of ALN-RSV01 or saline placebo in a nasal spray. Results showed that ALN-RSV01 was safe when administered intranasally in relevant doses to human volunteers, and comparable to placebo with respect to any reported adverse events. All reported adverse events for both ALN-RSV01 and placebo subjects were mild, with no reported serious adverse events. Further, there was no evidence of laboratory or electrocardiographic abnormalities in subjects exposed to drug. Finally, as expected, there was no significant systemic exposure of ALN-RSV01 when administered intranasally.
    
    "These data are an important milestone as we advance ALN-RSV01 into further clinical development. In the second half of this year we expect to initiate a Phase I study with an inhaled formulation of ALN-RSV01, and we are also actively exploring the initiation of an experimental infection, or 'viral challenge', study with our intranasal formulation in adult volunteers later in the year. We believe that these and other efforts will enable us to initiate a Phase II trial in naturally infected RSV patients in the first half of 2007," said Barry Greene, Chief Operating Officer of Alnylam. "Finally, as the industry's most advanced RNAi therapeutic for the treatment of infectious diseases, ALN-RSV01's development provides a critically important roadmap for our other pipeline efforts, including those with Novartis on pandemic influenza."
    
    The data from the Phase I trials are being presented at the 2006 Pediatric Academic Societies' (PAS) Annual Meeting being held in San Francisco, April 29 - May 2. Presentation of the results are taking place in two sessions: the State of the Art Plenary Session #3810 titled "RNA Interference, Technological Development of siRNAs and Potential Treatments for Childhood Diseases" to be held in Moscone West, Room 3016-3018 on April 30, 2006 at 4:15 p.m. PT; and the PAS/PIDS platform session #4130 titled "Infectious Diseases II" on May 1, 2006 at 8:00 a.m. PT in Moscone West, Room 3001.
    
    Trial Details
    
    The trial conducted in the U.S. enrolled 34 healthy adult volunteers. Drug or placebo was administered intranasally in single ascending doses (1.5, 5, 15, 50, or 150 mg) across five cohorts. The trial conducted in Europe enrolled 67 healthy adult volunteers. Drug or placebo was administered intranasally in both single ascending doses (5, 25, or 150 mg) across three cohorts and in multiple ascending doses (5, 25, and 150 mg) daily for five consecutive days across three cohorts. Dose levels administered were comparable to active anti-viral dose levels observed in pre-clinical animal studies. In both studies, ALN-RSV01 was evaluated for safety, tolerability, and pharmacokinetics.
    
    About Respiratory Syncytial Virus (RSV)
    
    RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a major cause of hospitalization due to respiratory infection in children and people with compromised immune systems, and others. RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, pneumonia, bronchiolitis, and in extreme cases, death. RSV infection in the pediatric population accounts for more than 100,000 hospitalizations per year in the U.S. In addition, RSV infection in infants has been linked to the development of childhood asthma. As a result, there is a significant need for novel therapeutics to treat patients who become infected with RSV.
    
    About RNA Interference (RNAi)
    
    RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are cau
13. [verwijderd] 1 mei 2006 18:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Met name deze quote:
    
    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that the company's lead product candidate, ALN-RSV01, was found to be safe and well tolerated when administered intranasally in two Phase I clinical studies. ALN-RSV01 is being evaluated for the treatment of respiratory syncytial virus (RSV) infection and is the first RNAi therapeutic in human clinical development for an infectious disease.
    
    Maakt de weg vrij voor Sirna !
    
14. [verwijderd] 1 mei 2006 18:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vraag me alleen af waarom Alny na een hogere opening nu 4% wegzakt onder een zeer laag volume...?
    
    finance.yahoo.com/q?s=alny
15. [verwijderd] 2 mei 2006 19:07

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nabeurs (in Amerika) zouden de resultaten over het 1e kwartaal 2006 worden gerapporteerd. Dit is echter voorbeurs gebeurd, zie hieronder:
    
    Sirna Therapeutics Reports First Quarter 2006 Financial Results
    Tuesday May 2, 7:36 am ET
    
    SAN FRANCISCO, May 2 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI - News) today reported financial results for the first quarter ended March 31, 2006.
    ADVERTISEMENT
    
    
    
    
    
    For the quarter ended March 31, 2006, Sirna reported a net loss of $8.0 million, or $0.13 per share, compared to a net loss of $8.0 million, or $0.19 per share, for the same period in 2005. Revenues for the first quarter of 2006 were $0.4 million, compared to $0.5 million for the same quarter in 2005.
    
    Operating expenses were $9.0 million for the three month period ended March 31, 2006 compared to $8.7 million for the same period in 2005. Operating expenses for the first quarter of 2006 included $0.7 million of non-cash share-based employee compensation expense, related to Sirna's adoption of Statement of Financial Accounting Standards No. 123R as of January 1, 2006. Excluding the share-based employee compensation expense, non-GAAP operating expenses for the first quarter of 2006 were $8.3 million and the non-GAAP net loss for the first quarter of 2006 was $7.3 million or $0.12 per share.
    
    Sirna ended the first quarter with $41.6 million in cash and marketable securities, and subsequently received $12.0 million from GlaxoSmithKline related to a collaboration agreement executed on March 31, 2006. The company's change in cash and marketable securities during the first quarter was $4.1 million, which reflects $7.5 million cash used in operations, offset by cash proceeds from warrant and option exercises of $3.4 million.
    
    "Sirna achieved two important goals this quarter," stated Howard W. Robin, Sirna President and CEO. "First, we signed a major respiratory alliance with GlaxoSmithKline (GSK). Second, we announced the issuance of a landscape- changing patent by the U.S. Patent Office (USPTO). We believe that the achievement of these goals, together with our progress in the clinic and our pioneering efforts to advance RNAi-based technology, will lead to even greater shareholder value."
    
    Recent highlights include:
    
    * The announcement of an exclusive multi-year strategic alliance with
    GlaxoSmithKline focused on discovery, development and commercialization
    of novel RNAi-based therapeutics for respiratory diseases. Sirna
    received an initial payment of $12.0 million, made up as cash and
    purchase of Sirna common stock, priced at $8.36 per share. Under the
    agreement, Sirna may also receive milestone payments in excess of
    $700.0 million for collaboration and clinical development events, as
    well as royalties on worldwide sales of products which successfully
    result from the alliance. In addition, Sirna will be eligible to
    receive contract manufacturing revenues. GSK will be responsible for
    all pre-clinical, development and commercialization expenses.
    
    * The issuance by the USPTO of the first broad siRNA patent for a gene
    target. The patent covers any chemically modified siRNA targeting I
    Kappa B kinase-gamma (IKK-gamma). The claims of the patent are not
    limited to a specific siRNA sequence, but cover any siRNA sequence used
    against the gene. This patent sets a precedent for Sirna's entire
    target patent portfolio in the U.S. Sirna has filed similar patents for
    use of siRNAs against over 250 mammalian gene and viral targets.
    
    * The issuance by the USPTO of a patent which broadly covers a process
    for the synthesis, deprotection and purification of nucleic acids with
    one or more ribonucleotides. This process is critical for the
    efficient synthesis of RNA at high yields and high purity and is
    applicable to both small- and large-scale production of
    oligonucleotides such as siRNAs and aptamers.
    
    * The appointment of R. Scott Greer, former Chairman of Abgenix, Inc., as
    the new Chairman of the Board of Directors and Lutz Lingnau, member of
    the Executive Board of Schering AG and Former President and Chief
    Executive Officer of Berlex Laboratories, as a new Board member.
    
    Howard W. Robin, Sirna President and CEO, and the Sirna senior management team will discuss progress to date in their clinical and preclinical programs and provide an overview of financial results during a conference call on Tuesday, May 2nd at 4:30 p.m. EDT (2:30 p.m. MDT; 1:30 p.m. PDT).
    
    A live audio webcast of the call will be available at the Company's corporate web site at www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. To access the live telephonic broadcast, domestic callers should dial (888) 802-2280; international callers may dial (913) 312-1266.
    
    An audio webcast replay will be available on Sirna's web site, www.sirna.com, for 60 days. Additionally, a telephonic replay of the call will be maintained through midnight, Tuesday, May 16, 2006. To access the replay, please dial (888) 203-1112 from the U.S. or (719) 457-0820 when calling internationally, using confirmation code 8556450.
    
    About Sirna Therapeutics
    
    Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology. Sirna Therapeutics completed its Phase 1 clinical trial for Sirna-027 in AMD in 2005 and with its strategic partner, Allergan, Inc., expects to move Sirna-027 into Phase 2 clinical trials in 2006. Sirna has selected a clinical compound for hepatitis C virus, Sirna-034, which the Company plans to bring into Phase 1 clinical trials by the end of 2006. Sirna has established an exclusive multi-year strategic alliance with GlaxoSmithKline for the development of siRNA compounds for the treatment of respiratory diseases. Sirna has a leading intellectual property portfolio in RNAi covering over 250 mammalian gene and viral targets and over 175 issued or pending patents covering other major aspects of RNAi technology. More information on Sirna Therapeutics is available on the Company's web site at www.sirna.com.
    
    Safe Harbor Statement
    
    Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, most drug candidates do not become approved drugs. Sirna currently does not have any clinical drug candidates for the treatment of respiratory diseases, and the development of Sirna-027 and Sirna-034 as well as Sirna's other programs are still at a relatively early stage. All of these programs, and Sirna's ability to obtain milestone and royalty payments for them, are subject to significant risks and unknowns,, are highly contingent upon future successes, and require significant funding. In addition, patent applications may not result in issued patents, and issued patents may not be enforceable or could be invalidated. Other risks and uncertainties include, among others, Sirna's early stage of development and short operating history, Sir
16. [verwijderd] 4 mei 2006 19:27

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Blijkbaar nog niemand opgevallen, maar onderstaand bericht maakt maar weer eens duidelijk in wat een miljardenmarkt Sirna zich begeeft.
    
    Let maar op: dit is de nieuwe Crucell in-wording !
    
    Press Release Source: Sirna Therapeutics, Inc.
    
    Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline
    Thursday May 4, 7:36 am ET
    Companies Initiate RNAi-based Therapeutic Effort Against Asthma and RSV
    
    SAN FRANCISCO, May 4 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI - News), a leading RNAi therapeutics company, today announced that as part of its exclusive, multi-year collaboration with GlaxoSmithKline (GSK) in respiratory diseases, the companies have initiated programs in asthma and respiratory syncytial virus (RSV). As part of the respiratory collaboration, the companies also plan to pursue RNAi-based therapeutics against chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Sirna will provide GSK with optimized and formulated siRNAs against targets for these diseases and GSK will assume all responsibility for the further preclinical and clinical development of compounds that emerge from these programs.
    ADVERTISEMENT
    
    
    RNA interference (RNAi) is a natural, selective process for turning off genes. Sirna designs and develops short interfering RNA (siRNA) compounds which down regulate the expression of critical proteins responsible for viral replication and pathogenesis. GSK is a world leader in the discovery and development of treatments for respiratory diseases and has a wealth of expertise in inhaled and intranasal drug delivery technologies. Local delivery of siRNA to the respiratory tract will substantially enhance the feasibility of developing successful treatments with this exciting new platform technology.
    
    "Sirna has demonstrated the ability to develop chemically modified and optimized siRNA compounds and then deliver those compounds effectively into the lung with our nanoparticle formulations," stated Barry Polisky, PhD, Chief Scientific Officer at Sirna. "Further, we have demonstrated that our proprietary approach to targeting the conserved region of a viral genome has resulted in significant viral knockdown in a non-human primate model. With these encouraging results and together with the combined efforts of Sirna and GSK scientific teams, we expect to expedite the development of novel RNAi-based therapies -- those efforts initially focused on asthma and RSV."
    
    Sirna is the first company to file enabling patents for over 250 important mammalian disease targets including respiratory targets such as MMP-13, IL-4, IL-13, VCAM, and ICAM as well as antiviral targets such as RSV. In addition, Sirna has been granted patent claims in the U.K. and has pending claims in the U.S. that broadly cover any siRNA molecule that targets conserved sequences within a virus or a gene.
    
    COPD is a disorder characterized by shortness of breath, chronic cough and sputum production. Cigarette smoking is the predominant etiologic factor in the development of COPD, and The World Health Organization (WHO) estimates the prevalence of COPD to be 600 million worldwide. By the year 2020, COPD is expected to be the third leading cause of death and the fifth leading cause of disability. Asthma is a chronic respiratory disease that currently affects 15 million people in the U.S., causes approximately 5,000 deaths per year and accounts for an estimated $13 billion in annual healthcare costs. Allergic rhinitis (AR) results from a local defense mechanism in the nasal airways that attempts to prevent irritants and allergens from entering the lungs. AR affects approximately 20% of the U.S. population. Over-the-counter treatments are estimated to be approximately $55 billion dollars per year and prescription medications exceed $6 billion per year worldwide. The financial impact of lost productivity is estimated to be $1.5 billion dollars per year. Respiratory syncytial virus is a highly infectious agent affecting children under the age of two. RSV can lead to serious lower respiratory infections such as pneumonia and can be fatal to infants born with lung or heart problems.
    
    
17. [verwijderd] 8 mei 2006 18:01

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Inmiddels noteren we weer boven de $8; dit is een typisch aandeel waarvan je over 1-2 jaar zegt: had ik er toen maar 1 of 2k ervan gekocht voor de LT.
    
    Miljardenmarkt; alles nog pril (fase I) maar een pijplijn waar je u tegen zegt en veelzeggende partners. Voor verdere info: www.sirna.com/wt/page/index
    
    Heb nu 2,5k die ik niet meer loslaat de komende jaren. Ik voorspel een eindejaarskoers van minimaal $20.
    
18. [verwijderd] 9 mei 2006 10:18

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    meneer sonny, voorspellingen doen met dit aandeel is geen goed idee ;( Heb ik ook wel eens gedaan verloop is te onvoospelbaar. Hopelijk komt daar verandering van het potentieel is er zeker. $50 of $100 over een jaar of 5-10 zal echt niet raar zijn.
19. [verwijderd] 11 mei 2006 13:32

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    helemaal gemist gisteren. Niet dat het effect had, maar wel leuk voor de toekomst
    
    Sirna Therapeutics Licenses Worldwide Exclusive Rights to microRNA Technology from University of Massachusetts Medical School
    Wednesday May 10, 8:20 am ET
    License Covers Use of microRNA Technology for Therapeutics, Diagnostics and Laboratory Reagents
    
    SAN FRANCISCO, May 10 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI - News) a leading RNAi therapeutics company, announced today that it has signed an exclusive worldwide licensing agreement with the University of Massachusetts Medical School (UMMS) for the rights to patents covering microRNA (miRNA) technology for the modulation of gene expression. MicroRNA is involved in the RNA interference (RNAi) mechanism and can play a critical role in gene silencing. Blocking the function of miRNAs holds significant potential for the treatment of human disease. In addition to the modulation of gene expression by blocking miRNA function, miRNAs on their own can be used as therapeutic agents.
    ADVERTISEMENT
    
    
    Like short interfering RNAs (siRNAs), miRNAs are involved in the RNA interference (RNAi) mechanism. However, while siRNAs direct the cleavage of messenger RNA (mRNA) synthesized by a gene, microRNAs appear to predominantly block translation of proteins by binding to the mRNA. The mechanism by which siRNAs and miRNAs induce gene silencing are complementary to one another, thereby presenting a dual approach to harnessing the RNAi mechanism to down regulate pathogenic proteins and viruses.
    
    "Exclusive license to these Zamore miRNA patents, combined with Sirna's existing intellectual property on miRNA, gives our Company a leading patent position in the emerging area of miRNA technology and use of miRNA as therapeutic agents or targets," said Bharat Chowrira, Ph.D., Vice President, Legal Affairs and Chief Patent Counsel. "With these new patents, we have positioned ourselves to capitalize on a broad intellectual property estate, which now enables Sirna to pursue multiple RNAi-based therapeutic approaches."
    
    The methodology, invented by Phillip Zamore, Ph.D. professor of biochemistry & molecular pharmacology, and Gyorgy Hutvagner, Ph.D, both of UMMS, provides methods for inhibition of small RNA function, such as microRNA function in vitro and in vivo. Dr. Zamore and his colleagues developed an elegant system of using short pieces of oligonucleotides that bind to the target microRNAs and block their function, thereby modulating target gene expression. These oligonucleotides are referred to as the anti-RISC oligonucleotides. These patents describe methods that can be used not only for advancing RNAi basic research, but also for developing miRNA-based therapeutics.
    
    "This invention by Dr. Zamore and his colleagues represents a powerful approach for modulating miRNA function," said James P. McNamara, Ph.D., Executive Director of the Office of Technology Management at the University of Massachusetts Medical School. "We are pleased to license this technology exclusively to Sirna as we believe the Company is at the forefront of RNAi-based therapeutic development."
    
    The Zamore miRNA patents are solely owned by the University of Massachusetts. Under the terms of the agreement, Sirna has an exclusive worldwide license to these patents for all uses, including therapeutics, diagnostics, and research reagents. The financial terms of the license were not disclosed.
    
    About RNA interference
    
    RNA interference (RNAi) is a natural, selective process for turning off genes. RNAi is triggered by short interfering RNA (siRNA) molecules that engage a group of cellular proteins, known as RISC (RNA induced silencing complex). The RISC guides the siRNA to its target messenger RNA (mRNA, the messenger between DNA and proteins) by complementary base pairing for the targeted break-up of the mRNA, thus halting protein expression or viral replication. The RISC-siRNA-complex binds and cleaves multiple mRNA molecules in a catalytic fashion.
    
    About Micro RNA
    
    RNA interference (RNAi) is also mediated by short naturally occurring double-stranded RNA molecules known as microRNAs (miRNAs). A large number of miRNAs have been identified in mammalian cells and are believed to regulate the expression of genes and viruses. Aberrant expression of miRNAs has been linked with several diseases, and blocking the function of miRNAs can potentially be a powerful means of treating a number of these diseases.
    
    
20. [verwijderd] 11 mei 2006 21:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hallo allemaal,
    
    Na er een half jaar uit te zijn geweest (RNAI $ 3,20 -> bad timing) heb ik weer tijd om aandelen te volgen en kopen.
    Ik ben natuurlijk gelijk weer in SIRNA gestapt.
    Anna heb jij momenteel nog andere pareltjes in gedachte, die ik eventueel weer kan oppakken>
    
    Groet,
    
    Elrond
21. gustaaf1e 11 mei 2006 22:33

    auteur info

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 25 mrt 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Anna,
    ik had dat bericht wel gezien gisteren. Vreemd genoeg toch forse daling. Zal ook wel tgv de algemene stemming zijn.
    Even kijken wanneer er een goed instapmoment is vanaf morgen.
    
    Guus